Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585587 | 1.00 | KDM4C (0.40) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL5585590 | 1.00 | KDM4C (0.40) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL5585591 | 0.82 | MEN1 (0.45) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL5585743 | 0.76 | KDM4C (0.39) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL3114026 | 0.76 | KDM4C (0.46) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL12635011 | 0.75 | KMT2A (0.39) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL5585308 | 0.74 | KDM4C (0.45) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL10051458 | 0.73 | KDM4C (0.44) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL5585297 | 0.73 | PDE5A (0.38) | — | |
| SCHEMBL5585291 | 0.73 | PDE5A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226925-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2007-06-05 | — | — | US | disclosed |
| EP-1513831-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040029888-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-12 | — | — | US | disclosed |
| WO-2004000830-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029888-A1 | Novel compounds, their use and preparation | TPH1, TPH2, HTR1A | KDM4C 3366/4885NPC1 421/4885RAB9A 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.